Successful Treatment with Paclitaxel of Advanced AIDS-associated Kaposi's Sarcoma.

Abstract

Kaposi's sarcoma (KS) is the most prevalent AIDS-associated tumor. Wereport a 44-year-old Japanese manwith advanced AIDS-associated KS, which was spread over bilateral pulmonary parenchyma. He was initially treated with combination chemotherapy with a partial response.Uponthe recurrence of his KStwo months after the completion of the combination chemotherapy, the patient received paclitaxel, which brought about a complete response. Highly active antiretrovial therapy (HAART) was initiated three months before the combination chemotherapy, and the CD4+T-cell count had risen before starting paclitaxel. His clinical course suggests that paclitaxel was highly effective for KS disease control as previously reported, and that immunerestoration with HAART is crucial in the treatment of KS.

Endoscopic resection for the diagnosis of visceral Kaposi?s sarcoma

“…Several cases of successful treatment with Paclitaxel have been reported recently. 35,36 We also applied a single use of Paclitaxel with 100 mg/m 2 every 3 weeks to this patient. The therapeutic effect was satisfactory, and the gastric lesions had almost disappeared 2 years later.…”

Investigation of Tubulin Polymerizing Agents: Synthesis of Substituted Cyclooctatrienes as a Possible Taxoid Framework

“…1) was the first of a group of compounds found to promote the polymerization of α-and β-tubulin subunits into microtubules and inhibit its subsequent disassembly during the next stage of mitosis [1,2]. It is one of the leading treatments for breast and ovarian cancer and was more recently approved for the treatment of non-small cell lung cancer and Kaposi's carcinoma, a common cancer among AIDS patients [3,4]. Paclitaxel (1) is a complex diterpene structure consisting of a 6-8-6-4 membered, fused ring system termed the "taxoid" backbone.…”